Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2022-07-31 Interim / Quarterly Rep…
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 827.8KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Cash Flow Statement & Operational Highlights' for the quarter ended June 2022. It includes detailed financial data such as cash flows from operating, investing, and financing activities, cash balances, payments to related parties, and compliance statements referencing ASX Listing Rule 4.7B. The presence of a detailed Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities to report quarterly cash flows, confirms this is a quarterly report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but the actual report itself. Therefore, the correct classification is Interim / Quarterly Report (IR).
2022-07-31 English
Corporate Presentation - Aussie Equities Day 2022 21 pages 2.3MB
Investor Presentation Classification · 95% confidence The document is titled 'Corporate Presentation Aussie Equities Day 2022' and contains detailed information about the company's management structure, technology platform, product pipeline, scientific data, and market context. It is structured as a presentation with disclaimers, future outlook, and scientific explanations, typical of investor or corporate presentations. There is no indication that this is a formal regulatory filing, annual or interim report, earnings release, or legal proceeding. The length (15,000 characters) and content suggest it is a full presentation rather than a brief announcement or certification. Therefore, the document best fits the category of an Investor Presentation (IP).
2022-07-27 English
Dr Philip Sutton - V.P. of Translational Sciences 2 pages 303.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the appointment of a new Vice President of Translational Sciences at Recce Pharmaceuticals. It focuses on management changes and does not contain financial data, regulatory certifications, or report publication notices. The content is clearly about a senior management appointment, which fits the Board/Management Information category.
2022-07-10 English
Phase I Positive Safety Data - 4000mg Complete 3 pages 249.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement reporting positive safety data from a Phase I clinical trial of a pharmaceutical product. It includes details about the trial cohort, dosing, safety review, and company commentary. There is no indication that this is a full financial report, audit, or regulatory filing. It is a clinical trial update announcement related to the company's drug development progress. This type of document fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial progress and not a financial or governance report.
2022-06-20 English
Cleansing Statement 1 page 208.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Cleansing Notice Under Section 708A(5)(E) of the Corporations Act'. It details the issuance of fully paid ordinary shares and compliance statements under the Corporations Act. The document is short (1354 characters) and serves as a regulatory notice about a share issue without full disclosure. It does not contain financial statements or detailed financial data, nor is it a full report. It is an announcement related to capital raising and share issuance compliance. Therefore, it fits best under 'Capital/Financing Update (CAP)'.
2022-06-16 English
Conversion of Performance Shares 1 page 191.6KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement regarding the conversion of performance shares into fully paid ordinary shares. It discusses a corporate action related to share conversion following a resolution of a dispute. There is no financial report, earnings data, or detailed financial statements included. The document is short (2602 characters) and focuses on a capital structure change involving shares. This fits the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues or capital changes such as conversions of performance shares.
2022-06-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.